Ovarian Cancer: New Treatment Standard?
- CHICAGO — Adding relacorilant to nab-paclitaxel substantially improved survival for women battling platinum-resistant ovarian cancer, according to the phase 3 ROSELLA trial presented at the ASCO Annual Meeting.
- The combination marks the first regimen to demonstrate improvements in both progression-free survival (PFS) and overall survival (OS) compared to weekly taxane alone.
- According to Olawaiye, director of gynecologic cancer research at Magee-Women’s Hospital of University of Pittsburgh, "This is a potential new standard, without any doubt." He further noted the...
The ROSELLA trial presents a compelling case: relacorilant combined with nab-paclitaxel considerably extends survival for women with platinum-resistant ovarian cancer. This cutting-edge ovarian cancer treatment shows promise, potentially revolutionizing how we combat this aggressive disease. Researchers observed a significant cut in the risk of disease progression or death, sparking excitement within the oncology community. This regimen marks a first, demonstrating improvements in both progression-free and overall survival. News Directory 3 delivers this essential update, highlighting the groundbreaking data presented at the ASCO Annual Meeting. This combination could become a new standard, providing a much-needed boost for those battling this challenging form of cancer. Discover what’s next in ovarian cancer treatment.
“`html
Relacorilant plus Nab-Paclitaxel Shows Promise in ovarian Cancer Treatment
Updated June 02, 2025
CHICAGO — Adding relacorilant to nab-paclitaxel substantially improved survival for women battling platinum-resistant ovarian cancer, according to the phase 3 ROSELLA trial presented at the ASCO Annual Meeting. the study suggests this combination could be a new standard for ovarian cancer treatment.
The combination marks the first regimen to demonstrate improvements in both progression-free survival (PFS) and overall survival (OS) compared to weekly taxane alone. Alexander b. Kanalaey, MD, the study’s principal investigator, expressed his enthusiasm, calling the results “elating.”
According to Olawaiye, director of gynecologic cancer research at Magee-Women’s Hospital of University of Pittsburgh, “This is a potential new standard, without any doubt.” He further noted the personal significance of the data unblinding, expressing joy in contributing to a treatment that could benefit many women.
Confirmatory Trial Details
Most ovarian cancers are diagnosed at advanced stages, III or IV, limiting treatment options. Many women eventually develop resistance to available therapies, Olawaiye noted.
Relacorilant, developed by Corcept Therapeutics, is an investigational selective glucocorticoid receptor antagonist. It aims to enhance tumor sensitivity to chemotherapy-induced apoptosis. Prior phase 2 studies suggested that adding relacorilant to nab-paclitaxel improved PFS in women with platinum-resistant ovarian cancer, with similar safety profiles to nab-paclitaxel alone.
Olawaiye explained that the phase 2 trial included women with platinum-refractory disease, a high-risk group. The statistically meaningful PFS advancement and a trend toward improved OS prompted the confirmatory trial.
‘Extraordinary benefit’ Observed
The ROSELLA trial, a global, open-label study